High Prevalence of ESBL-Producing Enterobacteriaceae and Antimicrobial Resistance Patterns in a Tertiary Care Hospital in Mogadishu, Somalia: A Retrospective Cross-Sectional Study Authors: Liban Abdi Nor, Ahmed Hassan Ibrahim, Serpil Doğan, Hanan Hassan Hirei, Said Mohamed Mohamud, Abdulrahman Nor Abdi, Yahye Sheikh Abdulle Hassan Published: 2026 ABSTRACT AbstractBackgroundExtended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae are a major global public health threat because of resistance to third-generation cephalosporins and frequent multidrug resistance. Data from Somalia remain limited. This study determined the prevalence of ESBL production, antimicrobial resistance patterns, and associated clinical and demographic factors.MethodsA retrospective cross-sectional study was conducted on 369 non-duplicate clinical Enterobacteriaceae isolates collected from inpatient and outpatient departments of a tertiary care hospital in Mogadishu, Somalia, between April and December 2025. ESBL production was detected using the combination disc test according to Clinical Laboratory Standards Institute (CLSI) guidelines. Antimicrobial susceptibility testing was performed using the Kirby–Bauer disk diffusion method and E-test. Multidrug resistance (MDR) was defined as resistance to at least one agent in three or more antimicrobial classes. Associations were assessed using Pearson’s chi-square test.ResultsOverall, 71.27% (263/369) of isolates were ESBL producers and 48.78% (180/369) were MDR. Escherichia coli (59.35%) was the predominant isolate, followed by Klebsiella spp. (30.62%) and Enterobacter spp. (5.15%). High resistance (>68%) to third- and fourth-generation cephalosporins was observed across major species. Meropenem resistance was highest in Enterobacter spp. (63.16%). Hospital department was significantly associated with ESBL production (p = 0.003) and MDR (p = 0.004), with the highest burden in the intensive care unit. Gender was associated with ESBL production (p = 0.034), while organism type was associated with MDR (p = 0.044).ConclusionThe high prevalence of ESBL-producing and multidrug-resistant Enterobacteriaceae, particularly in intensive care settings, highlights the need for strengthened antimicrobial stewardship, enhanced infection prevention and control, and continuous antimicrobial resistance surveillance.Keywords: extended-spectrum β-lactamase ESBL, Enterobacteriaceae, antimicrobial resistance, tertiary hospital, Somalia Background Antimicrobial resistance (AMR) constitutes a significant global public health challenge in the twenty-first century, jeopardizing the efficient prevention and treatment of infectious illnesses. Antimicrobial resistance (AMR) arises when microorganisms, such as bacteria, viruses, fungi, and parasites, evolve mechanisms that diminish the effectiveness of antimicrobial drugs, resulting in treatment failure, extended hospitalization, heightened transmission, and higher mortality.1,2 Besides clinical ramifications, AMR exerts significant economic and healthcare system pressures globally. In Gram-negative bacteria, the development of extended-spectrum beta-lactamase (ESBL) constitutes a significant resistance mechanism. Extended-spectrum beta-lactamases (ESBLs) are plasmid-encoded enzymes that hydrolyze Penicillin’s, third-generation cephalosporins, and monobactams, while typically being vulnerable to inhibition by beta-lactamase inhibitors such as clavulanic acid, tazobactam, and sulbactam. The plasmid-associated characteristics of ESBL genes promote horizontal gene transfer, expediting their spread in both healthcare and community environments. Besides clinical consequences, AMR inflicts significant economic and healthcare system burdens globally. ESBL generation is predominantly observed in Escherichia coli and Klebsiella species, while it is increasingly recognized in additional members of the Enterobacteriaceae family.3 ESBL-producing Enterobacteriaceae (ESBL-PE) are frequently associated with urinary tract infections, bloodstream infections, intra-abdominal infections, and healthcare-related infections. These diseases frequently require treatment with carbapenems or other last-resort medicines, therefore facilitating the development of further resistance. The World Health Organization (WHO) has identified ESBL-producing Gram-negative bacteria as priority pathogens for immediate research and the development of novel antimicrobial treatments due to their clinical significance.4 The worldwide impact of antimicrobial resistance is significant and increasing. Recent estimates suggest that bacterial antimicrobial resistance (AMR) was linked to roughly 4.71–4.95 million fatalities globally from 2019 to 2021, with 1.14–1.27 million deaths directly resulting from drug-resistant infections. In the absence of effective measures, antimicrobial resistance (AMR) may lead to approximately 1.91 million attributable deaths each year by 2050.5 ESBL-producing Gram-negative bacteria substantially exacerbate this issue due to their extensive resistance to first-line antimicrobial treatments. The consequences of AMR are especially pronounced in fragile and resource-constrained environments. In Somalia, restricted microbiological diagnostic capabilities, insufficient antimicrobial stewardship frameworks, inadequate infection prevention and control protocols, and pervasive unregulated access to antibiotics promote the swift growth and dissemination of resistance microorganisms. Available data indicate elevated resistance rates among Gram-negative isolates, especially E. coli. In 2019, Somalia was among the nations with the highest age-standardized mortality rates linked to antimicrobial resistance (AMR), with approximately 8,400 fatalities directly due to AMR and 32,700 deaths attributed to AMR-associated comorbidities.6 Nevertheless, extensive and properly gathered data from tertiary healthcare institutions in Mogadishu are still limited. This study seeks to ascertain the prevalence of ESBL-producing Enterobacteriaceae and to delineate their antibiotic susceptibility profiles among clinical isolates sourced from a tertiary care hospital in Mogadishu, Somalia. Producing context-specific epidemiological research is crucial for informing empirical treatment guidelines, enhancing antimicrobial stewardship programs, and bolstering national AMR surveillance operations. Materials and Methods Study Design and Setting A retrospective cross-sectional study was conducted at Mogadishu Somali–Türkiye Recep Tayyip Erdoğan Training and Research Hospital, the only tertiary teaching hospital and the main referral health center located in Mogadishu, Somalia. The hospital has an estimated capacity of 250–300 beds and serves as the principal national referral institution, providing care to approximately 250,000–300,000 patients annually from Mogadishu and other regions of Somalia. The hospital offers comprehensive clinical and diagnostic services and operates a central microbiology laboratory that processes specimens from both inpatient and outpatient departments. Study Population The study included all patients whose clinical specimens were submitted for bacterial culture and antimicrobial susceptibility testing between April12025and 30, December 2025. Patients of all age groups and both sexes from inpatient wards and outpatient clinics were consecutively enrolled. Specimens were included if they yielded bacterial growth with complete organism identification and antimicrobial susceptibility testing results. Exclusion criteria comprised duplicate isolates from the same patient, incomplete laboratory records, cultures with no bacterial growth, and contaminated specimens. Specimen Collection and Microbiological Procedures Clinical specimens including urine, blood, wound swabs, sputum, and other body fluids were collected by trained healthcare personnel using aseptic techniques in accordance with institutional clinical protocols. Specimens were properly labeled and transported promptly to the microbiology laboratory for processing. Blood cultures were obtained following recommended standards regarding collection volume and timing. Other specimens were collected in sterile, leak-proof containers and processed without delay. Upon receipt, specimens were inoculated onto appropriate culture media, including blood agar, Eosin Methylene Blue agar, and chocolate agar, and incubated at 35–37°C for 18–48 hours depending on specimen type and suspected pathogens. Bacterial identification was performed using colony morphology, Gram staining, and conventional biochemical tests including Triple sugar iron (TSI) agar, citrate utilization test, Motility indole Ornithine decarboxylase (MIO) and urease were used for identification of Enterobacteriaceae. Antimicrobial Susceptibility Testing Antimicrobial susceptibility testing was carried out using the Kirby–Bauer disk diffusion method and the E-test on Mueller–Hinton agar pure well-isolated colonies from an overnight culture were selected, emulsified in 5mL sterile normal saline solution. The bacterial suspension turbidity was compared with a 0.5 McFarland standard. After preparation of the inoculum suspension, Muller-hinton agar (Bioanalyse, Türkiye) was inoculated and antibiotic discs were aseptically placed. The following antimicrobial agents were tested: amoxicillin/clavulanic acid (AMC 20/10 µg), cefotaxime (CTX 30 µg), ceftazidime (CAZ 30 µg), cefepime (FEP 30 µg), piperacillin/tazobactam (TPZ 100/10 µg), ciprofloxacin (CIP 5 µg), gentamicin (GN 10 µg), amikacin (AMK 30 µg), trimethoprim/sulfamethoxazole (SXT 1.25/23.75 µg), meropenem (MEM 10 µg), nitrofurantoin (F 300 µg), and fosfomycin (F 50 µg) (Bioanalyse, Türkiye). Following incubation at 35–37°C for 16–18 hours, inhibition zone diameters were measured in millimeters and interpreted as susceptible, intermediate, or resistant according to CLSI breakpoint criteria.7 Multidrug resistance (MDR) was defined as resistance to at least one antimicrobial agent in three or more antimicrobial classes. Quality control procedures were performed using reference strains Escherichia coli ATCC 25922 and Klebsiella pneumoniae ATCC 700603 to ensure the accuracy of antimicrobial susceptibility testing and ESBL detection. Detection of Extended-Spectrum β-Lactamase Production Screening As part of routine clinical microbiology testing, all Enterobacterales isolates underwent antimicrobial susceptibility testing using the Kirby–Bauer disk diffusion method according to the Clinical and Laboratory Standards Institute (CLSI) M100 (2020) guidelines. Isolates demonstrating reduced susceptibility to third-generation cephalosporins, defined as cefotaxime (zone diameter ≤27 mm) and/or ceftazidime (zone diameter ≤22 mm), were considered potential ESBL producers based on CLSI screening criteria. These screening results were routinely generated during patient care and were retrospectively extracted from the laboratory information system for the present study.7 Phenotypic Confirmation of ESBL Because the present study specifically investigated the prevalence of ESBL-producing Enterobacterales, all isolates identified as potential ESBL producers during routine screening were retrieved from the laboratory collection and underwent phenotypic confirmatory testing for research purposes. Confirmation was performed using the CLSI-recommended combination disk method with ceftazidime (30 μg) and cefotaxime (30 μg), alone and in combination with clavulanic acid (30/10 μg), on Mueller–Hinton agar inoculated with a standardized 0.5 McFarland bacterial suspension. Plates were incubated aerobically at 35–37°C for 18–24 hours. An increase of ≥5 mm in the inhibition zone diameter for either antimicrobial agent tested in combination with clavulanic acid compared with the corresponding agent alone was interpreted as confirmation of ESBL production according to CLSI M100 (2020).7 Data Collection and Statistical Analysis Demographic information (age and sex), clinical variables (specimen type and hospital ward/unit), and microbiological results were obtained from the laboratory information system and patient records. The data were input into Microsoft Excel (Microsoft Corp., Redmond, WA, USA), validated for precision, and subsequently exported to R statistical software v4.1.2 for analysis. Descriptive statistics were employed to ascertain the prevalence of ESBL-producing isolates across various specimen types, hospital wards, and patient demographics. Categorical variables were summarized with frequencies and percentages, whereas continuous variables were presented as means ± standard deviations or medians with interquartile ranges. Relationships between variables were examined using Pearson chi-square tests, with significance established at p<0.05. The χ2-test assessed the relationships between MDR status and demographic characteristics, such as age group, sex, ICU ward, specimen type, and organism species. Ethical Approval This study was approved by the Clinical Research Ethics Committee of Mogadishu Somalia-Turkey Recep Tayyip Erdoğan Training and Research Hospital (Approval No: MSTH/23857). Results Demographic and Clinical Characteristics of Patients with ESBL-Producing Isolates (N=369) Table 1 summarizes, the descriptive characteristics of the total sample of 369 clinical specimens collected from patients in the different departments of the Recep Tayyip Erdoğan Hospital in Mogadishu, Somalia the baseline demographic and clinical distribution of the study population, which had a mean age of 44.8 ± 25.3 years. The largest age demographic represented was patients aged >50 years (42.28%), with a majority of isolates recovered from males (55.83%) and inpatients (72.90%). Clinically, the highest concentrations of isolates originated from the Surgery (29.54%) and ICU (28.73%) departments. Microbiological analysis identified Escherichia coli as the dominant pathogen, accounting for 59.35% of the isolates, followed by Klebsiella Spp (30.62%) and Enterobacter Spp (5.15%), establishing a microbiological landscape primarily composed of enteric Gram-negative bacilli (Table 1). Table 1Demographic and Clinical Characteristics of Patients with ESBL-Producing Isolates (N=369)CharacteristicFrequency (n)Percentage (%)Age (Years)Mean ± SD44.8±25.3—≤205815.72%21–307520.33%31–404612.47%41–50349.21%>5015642.28%GenderMale20655.83%Female16344.17%Patient CategoryInpatient26972.90%Outpatient10027.10%DepartmentSurgery10929.54%ICU10628.73%Internal Medicine7420.05%Infectious Diseases359.49%Pediatric112.98%Emergency102.71%Gynecology and Obstetrics92.44%Ear, Nose, Throat (ENT)71.90%Burn &wound41.08%Dialysis41.08%Isolated OrganismEscherichia coli21959.35%Klebsiella Spp11330.62%Enterobacter Spp195.15%Proteus Spp164.34%Serratia marcescens20.54% Demographic and Clinical Characteristics of Patients with ESBL-Producing Isolates (N=369) Comparative Analysis of Antimicrobial Resistance (AMR) Rates Among Major ESBL-Producing Pathogens Table 2 details a profound species-dependent resistance gradient among the three primary pathogens across several antibiotic classes. Notably, Enterobacter Spp exhibited a critically high resistance rate to the carbapenem, meropenem (63.16%), which was significantly higher than the rates observed in Klebsiella Spp (30.97%) and E. coli (14.16%). A similar pattern was observed for Amikacin, where resistance peaked at 63.16% in Enterobacter Spp. All three pathogens demonstrated extensive resistance to third- and fourth-generation cephalosporins (cefotaxime, ceftazidime, and cefepime), with resistance rates exceeding 68% across all groups. Furthermore, Enterobacter Spp showed extreme resistance to oral and urinary agents, including 80% resistance to Nitrofurantoin, while E. coli remained the most susceptible to urinary agents including both Nitrofurantoin and Fosfomycin (Table 2). Table 2Comparative Analysis of Antimicrobial Resistance (AMR) Rates Among Major ESBL-Producing PathogensAntibiotic CategoryAntibiotic (Code)E. coli (n=219)Resistant n(%)Klebsiella Spp (n=113)Resistant n(%)Enterobacter Spp (n=19)Resistant n(%)Last-ResortMeropenem (MEM)31 (14.16%)35 (30.97%)12 (63.16%)AminoglycosidesAmikacin (AK)26 (11.87%)38 (33.63%)12 (63.16%)Gentamicin (GN)63 (28.77%)49 (43.36%)14 (73.68%)CephalosporinsCefotaxime (CTX)152 (69.41%)82 (72.57%)16 (84.21%)Ceftazidime (CAZ)152 (69.72%)84 (74.34%)16 (84.21%)Cefepime (FEP)150 (68.49%)80 (70.80%)15 (78.95%)FluoroquinolonesCiprofloxacin (CIP)123 (56.16%)58 (51.33%)14 (73.68%)Beta-lactam/InhibitorsAmoxicillin/Clavulanic acid (AMC)158 (72.15%)88 (77.88%)17 (89.47%)Urinary DrugsNitrofurantoin (F)38 (32.76%)*16 (59.26%)*4 (80.00%)*Fosfomycin (FF)29 (25.22%)*15 (55.56%)*5 (100.00%)*OthersSXT (sulfamethoxazole/trimethoprim)153 (69.86%)79 (69.91%)15 (78.95%)Notes:*Sample sizes for Nitrofurantoin and Fosfomycin were smaller: E. coli (n=116), Klebsiella spp (n=27), and Enterobacter spp (n=5). Comparative Analysis of Antimicrobial Resistance (AMR) Rates Among Major ESBL-Producing Pathogens Notes:*Sample sizes for Nitrofurantoin and Fosfomycin were smaller: E. coli (n=116), Klebsiella spp (n=27), and Enterobacter spp (n=5). Prevalence of ESBL and MDR Among Isolates (N=369) Table 3 illustrates the overall burden of antimicrobial resistance within the clinical isolate pool. The overall phenotypic prevalence of Extended-Spectrum β-Lactamase (ESBL) production was alarmingly high at 71.27% (n=263). Additionally, nearly half of the isolates (48.78%, n=180) were classified as Multi-Drug Resistant (MDR), indicating resistance to at least three different antibiotic categories. These data underscore a critical public health challenge, as a vast majority of the recovered pathogens possess mechanisms that render standard β -lactam and several non- β-lactam therapeutic options ineffective (Table 3). Table 3Prevalence of ESBL and MDR Among Isolates (N=369)Resistance IndicatorFrequency (n)Percentage (%)ESBL ProductionYes26371.27%No10628.73%Multi-Drug Resistance (MDR)Yes18048.78%No18951.22% Prevalence of ESBL and MDR Among Isolates (N=369) Association Between Clinical/Demographic Factors and Resistance Status (N=369) Table 4 shows Bivariate analysis using Pearson chi-square tests was employed to identify clinical and demographic predictors of resistance. The hospital Department was identified as a highly significant predictor for both ESBL (p=0.003) and MDR (p=0.004) status, with the ICU serving as the primary reservoir for resistant strains. Gender was significantly associated with ESBL production (p=0.0034), with a higher prevalence among males. While ESBL production was widely distributed across species, MDR status was significantly associated with the specific Organism (p=0.0044), highlighting that Enterobacter Spp and Klebsiella Spp carry a disproportionately higher burden of multi-drug resistance. Factors such as age group (p=0.501), sample type (p=0.802), and patient category (p=0.269) did not demonstrate statistically significant associations with ESBL prevalence (Table 4). Table 4Association Between Clinical/Demographic Factors and Resistance Status (N=369)VariableESBL Positive (n=263)ESBL P-valueMDR Positive (N=180)MDR P-valueGender0.034*0.461Male156 (59.3%)104 (57.8%)Female107 (40.7%)76 (42.2%)Age Group0.5010.195≤2043 (16.4%)24 (13.3%)21–30 years48 (18.3%)33 (18.3%)31–40 years36 (13.7%)19 (10.6%)41–50 years25 (9.5%)17 (9.4%)>50 years111 (42.2%)87 (48.3%)Department0.003*0.004*ICU92 (35.0%)69 (38.3%)Surgery76 (28.9%)49 (27.2%)Internal Medicine45 (17.1%)28 (15.6%)Others50 (19.0%)34 (18.9%)Organism0.3520.044*E. coli153 (58.2%)104 (57.8%)Klebsiella Spp82 (31.2%)55 (30.6%)Enterobacter Spp17 (6.5%)15 (8.3%)Others11 (4.2%)6 (3.3%)Sample Type0.8020.443Urine98 (37.3%)67 (37.2%)Respiratory70 (26.6%)50 (27.8%)Wound61 (23.2%)41 (22.8%)Blood28 (10.7%)20 (11.1%)Others6 (2.3%)2 (1.1%)Patient Category0.2690.263Inpatient196 (74.5%)136 (75.6%)Outpatient67 (25.5%)44 (24.4%)Notes: *Statistically Significant at P–value <0.05. Association Between Clinical/Demographic Factors and Resistance Status (N=369) Notes: *Statistically Significant at P–value <0.05. Discussion The development of extended-spectrum β-lactamase (ESBL) by Enterobacteriaceae has become a significant global public health issue, severely undermining the efficacy of β-lactam antibiotics and limiting therapeutic alternatives. The swift spread of ESBL-producing bacteria, especially in healthcare environments, persists in complicating clinical management and laboratory identification.8 To the best of our knowledge, this study represents the first comprehensive report describing the prevalence and antimicrobial resistance patterns of ESBL-producing Enterobacteriaceae isolated from clinical specimens in Somalia. Our findings provide critical baseline data for antimicrobial stewardship initiatives and infection prevention strategies within the country. In our study, the phenotypic prevalence of ESBL production was alarmingly high at 71.27%, with nearly half of the isolates (48.78%) classified as multidrug-resistant (MDR). The findings reveal a significant prevalence of antimicrobial resistance in our institution, indicating that a considerable number of infections are attributable to organisms resistant to both first-line and multiple second-line treatments. A similar prevalence of ESBL has been documented in Ethiopia (67.3%).9 while even higher rates have been documented in Ghana (76.06%).10 The high prevalence noted in our study may indicate extensive empirical antibiotic utilization, insufficient antimicrobial stewardship initiatives, and inadequate infection prevention strategies. The regional commonalities emphasize the extensive antibiotic resistance crisis in sub-Saharan Africa and show the pressing necessity for synchronized national and regional surveillance systems. These findings highlight the need to strengthen antimicrobial stewardship in Somalia through the implementation of evidence-based antibiotic prescribing guidelines, routine culture and antimicrobial susceptibility testing to guide therapy whenever feasible, regular review and de-escalation of empirical antibiotic treatment based on microbiological results, and continuous education of healthcare professionals on rational antimicrobial use. In addition, regular antimicrobial resistance surveillance, local antibiogram updates, and integration of stewardship with infection prevention and control programs are essential to optimize empirical therapy and limit the spread of ESBL-producing Enterobacteriaceae. In the current study, Infections were more prevalent in older adults, especially those over 50 years of age, with a little male predominance. This trend aligns with prior research11,12 and may indicate heightened comorbidities, recurrent healthcare interactions, and invasive interventions in older individuals. The bulk of isolates were predominantly sourced from hospitalized individuals (72.90%), highlighting the mostly nosocomial characteristics of ESBL-producing pathogens. A comparable inpatient majority has been noted in Chad.13 The greatest prevalence of isolates was observed in surgical wards and intensive care units, consistent with findings from Palestine and India, where surgical departments exhibited the highest burden of ESBL.11,14 These data indicate that surgical procedures, extended hospital stays, and exposure to intensive care may constitute significant risk factors in our context. According to our study, Escherichia coli was the leading pathogen (59.35%), followed by Klebsiella spp. (30.62%) and Enterobacter spp. (5.15%). The prevalence of E. coli, especially in urine samples, reflects the global epidemiology of ESBL.15,16 However, the significant percentage of respiratory isolates underscores the relevance of hospital-acquired pneumonia and ventilator-associated illnesses in our facility. The observed gradient in carbapenem resistance is particularly concerning. Enterobacter spp. exhibited the highest rates of phenotypic carbapenem resistance as determined by meropenem susceptibility tests. The absence of carbapenemase confirmation tests (mCIM/eCIM) precluded the determination of carbapenemase-producing organisms”.17,18 The magnitude of resistance observed in our study raises concern regarding the potential emergence and establishment of carbapenem-resistant Enterobacteriaceae (CRE) in Somalia. Despite the decreased prevalence of carbapenem resistance in Klebsiella spp. compared to Enterobacter spp, it remains therapeutically pertinent. Research conducted in Saudi Arabia has indicated that carbapenem resistance rates in K. pneumoniae isolates surpass 60%.19 indicating that geographical variability is affected by antibiotic prescribing policies and infection control methods. Conversely, E. coli demonstrated relatively reduced carbapenem resistance, in accordance with previous findings.20,21 Nevertheless, even moderate resistance levels are concerning given that carbapenems are often reserved as last-line agents for severe ESBL infections. Resistance to aminoglycosides exacerbates treatment problems. The significant amikacin resistance detected in Enterobacter spp (63.16%) constrains combination therapy alternatives and may indicate the existence of aminoglycoside-modifying enzymes or 16S rRNA methyltransferases.22 Moreover, all three pathogens exhibited significant resistance to third- and fourth-generation cephalosporins, underscoring the enzymatic activity of ESBLs and corroborating data from other African contexts.16,23 Notably, Enterobacter spp. exhibit significant resistance to oral and urinary medicines, particularly to nitrofurantoin. E. coli exhibited comparatively greater susceptibility to urinary drugs; nonetheless, the declining efficacy of frequently prescribed oral antibiotics presents significant challenges for outpatient therapy of urinary tract infections and heightens dependence on parenteral treatments. Collectively, these fundings illustrate a significant and developing antimicrobial resistance environment in Somalia. The convergence of elevated ESBL prevalence, significant MDR rates, and the emergence of carbapenem resistance necessitates the urgent enhancement of antimicrobial stewardship programs, stringent infection prevention and control protocols, and the implementation of national antimicrobial resistance surveillance systems. Molecular epidemiology investigations are essential for identifying circulating resistance genes and monitoring transmission patterns. This study has several limitations. First, it was conducted at a single tertiary referral hospital, which may limit the generalizability of the findings to other healthcare settings in Somalia. Second, although ESBL production was confirmed phenotypically using the CLSI-recommended combination disk method, molecular characterization of ESBL genes (eg, blaCTX-M, blaTEM, and blaSHV) was not performed. Similarly, although carbapenem susceptibility testing was routinely conducted using meropenem disc and E-tests, confirmatory phenotypic or molecular testing for carbapenemase production (eg, mCIM/eCIM or carbapenemase gene detection) was unavailable; therefore, carbapenem-resistant isolates could not be confirmed as carbapenemase-producing Enterobacterales. Third, extensively drug-resistant (XDR) isolates were not classified because the antimicrobial susceptibility panel was not sufficiently comprehensive to apply the internationally accepted XDR definition. Fourth, this retrospective laboratory-based study relied primarily on routinely collected microbiological and limited demographic data. Important clinical variables, including underlying comorbidities, prior antimicrobial exposure, invasive procedures, duration of hospitalization, catheterization, and mechanical ventilation, were not consistently available and therefore could not be evaluated. Consequently, multivariable logistic regression analysis to identify independent risk factors for MDR or XDR infections was not feasible. Despite these limitations, this study provides the first comprehensive data on the burden of ESBL-producing Enterobacterales and antimicrobial resistance patterns from a tertiary referral hospital in Somalia and establishes an important baseline for future multicenter prospective studies incorporating detailed clinical, molecular, and epidemiological data. Conclusion This study indicates a notably high prevalence of ESBL-producing Enterobacteriaceae (71.27%) and significant multidrug resistance (48.78%) in a tertiary care hospital in Mogadishu. Escherichia coli and Klebsiella spp. were predominant, whereas Enterobacter spp. exhibited particularly high levels of carbapenem resistance. Extensive resistance to cephalosporins, aminoglycosides, and certain last-resort medicines considerably restricts treatment alternatives and indicates an escalating danger of carbapenem-resistant Enterobacteriaceae in Somalia. The immediate execution of antibiotic stewardship, enhanced infection prevention protocols, and national resistance surveillance initiatives is crucial to curtail further dissemination and inform evidence-based treatment approaches. Acknowledgments The authors would like to thank the staff of the clinical microbiology laboratory at Mogadishu Somali–Türkiye Recep Tayyip Erdoğan Training and Research Hospital for their support in data collection and laboratory analysis. Funding Statement No external funding was received. Data Sharing Statement All data generated or analyzed during this study are included in this article and are available from the corresponding author on reasonable request. Ethical Approval and Consent to Participate Ethical approval was obtained from the Institutional Review Board of Mogadishu Somali–Türkiye Recep Tayyip Erdoğan Training and Research Hospital (Approval No: MSTH/23857). All data were anonymized prior to analysis to maintain patient confidentiality. As this study was retrospective and based solely on routine laboratory records, the requirement for informed consent was waived by the Institutional Review Board. All procedures were performed in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments. Author Contributions All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Disclosure The authors declare that they have no competing interests. References Associated Data Data Availability Statement All data generated or analyzed during this study are included in this article and are available from the corresponding author on reasonable request.